SELP and myocardial infarction: However, only a few clinical studies have directly tested anti-leukocyte therapies: Administration of the P-Selectin blocking antibody Inclacumab prevented myocardial damage after MI and a percutaneous coronary intervention (PCI) (Tardif et al., 2013; Stahli et al., 2016).